Methods and compositions for treating diseases and conditions associated with mitochondrial function
AssigneeThe Regents of the University of Michigan
InventorGary D. Glick
Life of this patent
Estimating the term…
Abstract
The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase associated disorders, and the like.
Claims18
A method of treating a disorder comprising inhibiting the activity of ATP synthase complexes in cells affected by said disorder through exposing said affected cells to a composition able to bind the oligomycin sensitivity conferring protein of said ATP synthase complexes, wherein said disorder is selected from the group consisting of a bacterial infection, a viral infection, a fungal infection, a parastitic infection, a disorder involving aberrant angiogenesis, a disorder involving aberrant blood pressure regulation, and a disorder involving aberrant HDL/LDL regulation.
A composition comprising a compound able to bind the oligomycin sensitivity conferring protein of a F1F0 ATPase, wherein said compound is selected from the group consisting of:
- or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug thereof, wherein:
- R1 and R5 are attached to any available carbon atom of phenyl rings A and B, respectively, and at each occurrence are independently selected from alkyl, substituted alkyl, halogen, cyano, nitro, OR8, NR8R9, C(═O)R8, CO2R8, C(═O)NR8R9, NR8C(═O)R9, NR8C(═O)ORg, S(O)0R9, NR8SO2R9, SO2NR8R9, cycloalkyl, heterocycle, aryl, and heteroaryl, and/or two of R1 and/or two of R5 join together to form a fused benzo ring;
- R2, R3 and R4 are independently selected from hydrogen, alkyl, and substituted alkyl, or one of R2, R3 and R4 is a bond to R, T or Y and the other of R2, R3 and R4 is selected from hydrogen, alkyl, and substituted alkyl;
- Z and Y are independently selected from C(═O), —CO2—, —SO2—, —CH2—, —CH2C(═O)—, and —C(═O)C(═O)—, or Z may be absent;
- R and T are selected from —CH2—, —C(═O)—, and —CH[(CH2)p(Q)]-, wherein Q is NR10R11, OR10 or CN;
- R6 is selected from alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl, heterocyclo, and heteroaryl;
- provided that where R2 is hydrogen, Z-R6together are not —SO2-Me
- or R7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aminoalkyl, halogen, cyano, nitro, keto (═O), hydroxy, alkoxy, alkylthio, C(═O)H, acyl, CO2H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamidyl, cycloalkyl, heterocycle, aryl, and heteroaryl;
- R8 and R9 are independently selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, heterocycle, aryl, and heteroaryl, or R8 and R9 taken together to form a heterocycle or heteroaryl, except R9 is not hydrogen when attached to a sulfonyl group as in SO2R9;
- R10 and R11 are independently selected from hydrogen, alkyl, and substituted alkyl;
- m and n are independently selected from 0, 1, 2 and 3;
- o, p and q are independently 0, 1 or 2;
- and r and t are 0 or 1;
- or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug thereof, wherein:
- R1 is selected from the group consisting of H, CN and SO2-piperidine;
- R2 is selected from the group consisting of H, 4-Cl-Ph, Ph, and 2-Me-imidazole;
- R3 is selected from the group consisting of H, CH2-2-imidazole, and CH2-2-oxazole;
- or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug thereof, wherein:
- R1 is selected from the group consisting of H, 2,4-Cl2, 2-4-Me2, and 2,5-(CF3)2;
- R2 is selected from the group consisting of H, 4-Cl, 4-Me, 2,4-Cl2, 2,4-Me2, 3-Cl;
- X is selected from the group consisting of O and NH;
- Y is selected from the group consisting of S, O, NCN, CO(3-CN-Ph), CO(4-CN-Ph), CO(4-Cl-Ph), and COEt;
- and
- or a pharmaceutically-acceptable salt or hydrate thereof, wherein:
- R1 is cyano, —SO2R8, —C(═O)R9, or heteroaryl;
- R2 is (i) independently hydrogen, alkyl, or subitituted alkyl, or (ii) taken together with R3 forms a heterocyclo;
- R3 is (i) independently selected from (a) alkyl optionally substituted with one to two of hydroxy and alkoxy;
- (b) alkylthio or aminoalkyl optionally substituted with hydroxy or alkoxy;
- (c) -A1-aryl, wherein the aryl is optionally substituted with up to four substituents selected from alkyl, substituted alkyl, halogen, haloalkoxy, cyano, nitro, —NR17R18, —SR17, —OR17, —SO2R17a, —SO2NR17R18, —NR17C(═O)R18, —CO2R17, —C(═O)R17, cycloalkyl, aryl, heterocyclo, and heteroaryl, and/or has fused thereto a five or six membered cycloalkyl ring;
- (d) -A2-heteroaryl wherein the heteroaryl is a five or six membered monocyclic ring having 1 to 3 heteroatoms selected from N, O, and S, or an eight or nine membered bicyclic ringed system having at least one aromatic ring and 1 to 4 heteroatoms selected from N, O, and S in at least one of the rings, said heteroaryl being optionally substituted with halogen, alkyl alkoxycarbonyl, sulfonamide, nitro, cyano, trifluoromethyl, alkylthio, alkoxy, keto, —C(═O)H, acyl, benzyloxy, hydroxy, hydroxyalkyl, or phenyl optionally substituted with alkyl or substituted alkyl;
- (e) -A2-hoterooyclo wherein the heterocyclo is optionally substituted with one to two groups selected from alkyl, keto, hydroxy, hydroxyalkyl, —C(═O)H, acyl, CO2H, alkoxycarbonyl, phenyl, and/or benzyl, and/or has a bridged carbon-carbon chain or fused benzene ring joined thereto;
- (f) -A2-cycloalkyl wherein the cycloalkyl is optionally substituted with one to two groups selected from alkyl, keto, —C(═O)H, acyl, CO2H, alkoxycarbonyl, and/or benzyl, and/or has a bridged carbon-carbon chain or fused benzene ring joined thereto;
- or (ii) taken together with R2 forms a heterocyclo;
- R4 at each occurrence is selected independently of each other R4 from the group consisting of halogen, alkyl, haloalkyl, intro, cyano, and haloalkoxy;
- R7a, R7b and R7c are alkyl, carbamyl, or carbamylalkyl, or R7a and R7c join to form an aryl or heteoraryl;
- R8 is alkyl, arylalkyl, or aryl;
- R9 is alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclo, or CO2R12;
- R10 is independently hydrogen, alkyl, or alkoxy;
- and R11 is independently hydrogen, alkyl, substituted alkyl, alkoxy heterocyclo cycloalkyl, aryl, or heteroaryl;
- or R10 and R11 taken together form a heterocyclo or heteroaryl optionally substituted with alkyl, keto, CO2H, alkoxycarbonyl, hydroxy, alkoxy, alkyl, carbamyl, aryl, or substituted alkyl, wherein when the R10 and R11 group comprises a phenyl ring, said phenyl ring is optionally substituted with one to two of alkyl, halogen, and alkoxy;
- R12 is hydrogen or alkyl;
- A1 is —(CHR14)m-V—(CR15R16)n— or —(CHR14)p—(C═O)NH—;
- A2 is —(CHR14)m-V—(CR15R16)n;
- V is a bond, S, or —NR22—;
- R14, R15 and R16 at each occurrence are independently selected from hydrogen, alkyl, hydroxy, hydroxyC1-4alkyl, C1-4alkoxy, and phenyl, and/or one of R15 and one of R16 join together to form a three to six membered cycloalkyl;
- R17 and R18 are independently selected from hydrogen, alkyl, pheziyl, and benzyl, wherein the phenyl and benzyl is optionally substituted with alkyl hydroxy, or hydroxyalkyl;
- R17a is alkyl or substituted alkyl;
- R22 is hydrogen or alkyl;
- m and n are 0, 1, 2 or 3;
- p is 0, 1, 2 or 3;
- and q is 0 1, 2 or 3.
Dependencies are inferred from the claim text.